Axial Spondyloarthritis Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 – DelveInsight | Janssen Pharma, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharma

Posted on
by

Axial Spondyloarthritis Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 – DelveInsight | Janssen Pharma, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharma
The Key Axial Spondyloarthritis Companies in the market include – Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others.

 

(Albany, New York) – October 20, 2026: DelveInsight’s report “Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Axial Spondyloarthritis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

 

Additionally, it examines Axial Spondyloarthritis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

 

To Know in detail about the Axial Spondyloarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axial Spondyloarthritis Market Forecast

 

Some of the key facts of the Axial Spondyloarthritis Market Report:

  • The Axial Spondyloarthritis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In September 2026, The Phase III BE MOVING long-term extension study, evaluating bimekizumab in patients with radiographic and non-radiographic axial spondyloarthritis, was marked completed on September 7, 2026. The study assessed long-term efficacy, safety, and tolerability.

  • In August 2026, Three-year results from the Phase III BE MOBILE 1 and BE MOBILE 2 studies were published in the Journal of Rheumatology on August 1, 2026. Clinical improvements were sustained through week 164, with 28.7% of patients achieving inactive disease by the ASDAS measure. No new safety signals were reported, although fungal infections, primarily Candida infections, remained an important safety consideration.

  • In July 2026, Grey Wolf Therapeutics’ investigational oral ERAP1 inhibitor was listed as actively recruiting in its Phase I/II EAST-1 trial as of July 22, 2026. The study is evaluating safety and tolerability, with expansion cohorts investigating its potential in axial spondyloarthritis.

  • In May 2026, A Phase II/III randomized clinical trial published in JAMA Network Open on May 8, 2026, reported positive results for vunakizumab, an investigational IL-17A inhibitor, in radiographic axial spondyloarthritis. At week 16, the ASAS20 response rate was 65.6% with vunakizumab 120 mg versus 42.5% with placebo. Benefits persisted through week 32, with a tolerable safety profile. The findings support further development; they do not establish FDA approval

  • In February 2026, MoonLake Immunotherapeutics announced positive topline Phase II S-OLARIS results on February 22, 2026. More than 80% of patients achieved an ASAS40 response by week 12, according to the company’s announcement. Improvements were also reported in disease activity and MRI/PET imaging measures, with no new safety signals identified. These are sponsor-reported topline results, not FDA approval.

  • In February 2026, MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotech firm focused on advancing innovative therapies for inflammatory diseases, has reported topline findings from the S-OLARIS Phase 2 trial of SLK in patients with radiographic and non-radiographic Axial spondyloarthritis (axSpA). The company also released its financial results for the fourth quarter and full year ending December 31, 2025. Additionally, an Investor Day webcast is scheduled for February 23, 2026, from 8:00 to 9:30 a.m. EST (2:00 to 3:30 p.m. CET), which will include a live Q&A session.

  • In January 2025, MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company developing advanced therapies for inflammatory diseases, announced that patient screening has begun for three new trials evaluating sonelokimab, an investigational Nanobody® therapy. These trials expand the clinical program to include adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA), alongside existing studies in adult patients with HS and active psoriatic arthritis (PsA).

  • BIMZELX is the first treatment approved for all three conditions, designed to selectively inhibit two key cytokines involved in inflammation interleukin 17A (IL-17A) and interleukin 17F (IL-17F). These approvals follow its initial U.S. approval in October 2023 for moderate-to-severe plaque psoriasis in adults eligible for systemic therapy or phototherapy.

  • According to DelveInsight, the total prevalent population of axial spondyloarthritis (axSpA) in the 7 major markets (7MM) was approximately 4,575,000 in 2023, and this figure is projected to increase significantly over the study period from 2020 to 2034.

  • Of these, about 3,981,346 individuals were identified as overall prevalent cases in the 7MM, with numbers expected to continue rising between 2024 and 2034.

  • DelveInsight estimates that the total prevalent population of axial spondyloarthritis (axSpA) in the 7 major markets (7MM) was approximately 4,575,000 in 2023, with a notable increase expected over the period from 2020 to 2034.

  • In the US, the diagnosed population of non-radiographic axSpA was around 569,000 cases in 2023. Among the EU4 and UK, Germany reported the highest number of prevalent axSpA cases, followed closely by Spain.

  • The US FDA has approved UCB’s CIMZIA, Eli Lilly’s TALTZ, Novartis’s COSENTYX, and AbbVie’s RINVOQ for the treatment of both radiographic (r-axSpA) and non-radiographic axial spondyloarthritis (nr-axSpA). In comparison, Immunex/Amgen’s ENBREL, Pfizer’s XELJANZ, and Johnson & Johnson’s SIMPONI are approved solely for ankylosing spondylitis. Additionally, LUMICEF is approved in Japan for both r-axSpA and nr-axSpA

  • Key Axial Spondyloarthritis Companies: Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others

  • Key Axial Spondyloarthritis Therapies: SIMPONI (golimumab), XELJANZ (tofacitinib), Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others

  • The Axial Spondyloarthritis epidemiology based on gender analyzed that the prevalent population of Axial Spondyloarthritis showed a male predominance, whereas, nr-axSpA showed female predominance.

  • The Axial Spondyloarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Axial Spondyloarthritis pipeline products will significantly revolutionize the Axial Spondyloarthritis market dynamics.

 

Axial Spondyloarthritis Overview

Axial Spondyloarthritis is a type of chronic inflammatory arthritis primarily affecting the spine and the sacroiliac joints, which connect the lower spine to the pelvis. This condition can lead to pain, stiffness, and decreased mobility in the affected areas. AxSpA encompasses two subtypes: non-radiographic axial spondyloarthritis (nr-axSpA), where there is no visible damage on X-rays, and ankylosing spondylitis (AS), where changes are visible on X-rays, including possible fusion of the vertebrae.

 

Get a Free sample for the Axial Spondyloarthritis Market Report:

https://www.delveinsight.com/report-store/axial-spondyloarthritis-market

 

Axial Spondyloarthritis Epidemiology

The Axial Spondyloarthritis epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Axial Spondyloarthritis Epidemiology Segmentation:

The Axial Spondyloarthritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalent Cases of Axial Spondyloarthritis in the 7MM

  • Total Diagnosed Cases of Axial Spondyloarthritis in the 7MM

  • Gender-specific Cases of Axial Spondyloarthritis in the 7MM

  • Gene-specific Cases of Axial Spondyloarthritis in the 7MM

  • Age-specific Cases of Axial Spondyloarthritis in the 7MM

  • Total Treated Cases of Axial Spondyloarthritis in the 7MM

 

Download the report to understand which factors are driving Axial Spondyloarthritis epidemiology trends @ Axial Spondyloarthritis Epidemiology Forecast

 

Axial Spondyloarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axial Spondyloarthritis market or expected to get launched during the study period. The analysis covers Axial Spondyloarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Axial Spondyloarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Axial Spondyloarthritis Therapies and Key Companies

  • SIMPONI (golimumab): Janssen Pharmaceuticals

  • XELJANZ (tofacitinib): Pfizer

  • Bimekizumab: UCB Biopharma

  • CC-99677: Celgene

  • ABY- 035: Inmagene Biopharmaceuticals

  • Filgotinib: Galapagos NV

  • KHK4827: Kyowa Kirin Co., Ltd.

  • Ixekizumab: Eli Lilly and Company

  • Golimumab: Merck Sharp & Dohme LLC

  • etanercept: Pfizer

  • Bimekizumab: UCB Biopharma

  • Secukinumab: Novartis

  • SHR0302: Jiangsu HengRui Medicine

  • Certolizumab Pegol: UCB Biopharma

 

Discover more about therapies set to grab major Axial Spondyloarthritis market share @ Axial Spondyloarthritis Treatment Market

 

Axial Spondyloarthritis Market Drivers

  • Rising prevalence and improved recognition of axSpA, including both radiographic (AS) and non-radiographic forms.

  • Strong adoption of biologics and targeted therapies, such as TNF inhibitors, IL-17 inhibitors, and JAK inhibitors.

  • Advancements in imaging technologies (MRI) and early diagnostic protocols facilitating timely treatment.

  • Updated clinical guidelines and growing reimbursement support improving patient access to advanced therapies.

  • Active R&D and robust pipeline of novel therapies, enhancing future treatment options.

 

Axial Spondyloarthritis Market Barriers

  • High cost of biologic therapies limiting accessibility for many patients.

  • Delay in diagnosis due to overlapping symptoms with other musculoskeletal disorders.

  • Side effects and long-term safety concerns associated with current treatment options.

  • Limited awareness about non-radiographic axSpA, leading to underdiagnosis in some populations.

  • Stringent regulatory requirements for novel therapies, potentially slowing market entry.

 

Scope of the Axial Spondyloarthritis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Axial Spondyloarthritis Companies: Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others

  • Key Axial Spondyloarthritis Therapies: SIMPONI (golimumab), XELJANZ (tofacitinib), Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others

  • Axial Spondyloarthritis Therapeutic Assessment: Axial Spondyloarthritis current marketed and Axial Spondyloarthritis emerging therapies

  • Axial Spondyloarthritis Market Dynamics: Axial Spondyloarthritis market drivers and Axial Spondyloarthritis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Axial Spondyloarthritis Unmet Needs, KOL’s views, Analyst’s views, Axial Spondyloarthritis Market Access and Reimbursement

 

To know more about Axial Spondyloarthritis companies working in the treatment market, visit @ Axial Spondyloarthritis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Axial Spondyloarthritis Market Report Introduction

2. Executive Summary for Axial Spondyloarthritis

3. SWOT analysis of Axial Spondyloarthritis

4. Axial Spondyloarthritis Patient Share (%) Overview at a Glance

5. Axial Spondyloarthritis Market Overview at a Glance

6. Axial Spondyloarthritis Disease Background and Overview

7. Axial Spondyloarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Axial Spondyloarthritis

9. Axial Spondyloarthritis Current Treatment and Medical Practices

10. Axial Spondyloarthritis Unmet Needs

11. Axial Spondyloarthritis Emerging Therapies

12. Axial Spondyloarthritis Market Outlook

13. Country-Wise Axial Spondyloarthritis Market Analysis (2020–2034)

14. Axial Spondyloarthritis Market Access and Reimbursement of Therapies

15. Axial Spondyloarthritis Market Drivers

16. Axial Spondyloarthritis Market Barriers

17. Axial Spondyloarthritis Appendix

18. Axial Spondyloarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/